CRISPR Tool Kills Cancer Cells by Reading Their RNA With Surgical Precision

A research team from Utah State University has published findings in Nature describing a CRISPR-based system capable of identifying and killing cells based on their RNA content. This is a meaningful advance because many dangerous cell states — cancer, viral infection — are defined by what RNA a cell expresses, not just what mutations exist in its DNA.

The core of the system is an enzyme called Cas12a2. When its guide RNA finds a matching RNA target inside a cell, the enzyme doesn't stop there. It enters an indiscriminate destruction mode, chopping up all double-stranded DNA in the cell, ultimately killing it. Prior work showed this works in bacteria, but human and yeast cells have sophisticated DNA repair systems that can race to patch damage before it becomes lethal.

The researchers first tested Cas12a2 in baker's yeast, reducing surviving colonies 134-fold compared to just 4-fold for a conventional CRISPR nuclease. They then moved to HeLa human cervical cancer cells and confirmed cell death. Expanding to six gene targets — including KRAS, EGFR, and TP53 — across four human cancer cell lines, killing was effective even for poorly expressed transcripts. Crucially, delivery was achieved using lipid nanoparticles, the same platform behind mRNA COVID vaccines, suggesting a viable therapeutic pathway.

Off-target safety was also assessed. When Cas12a2 was programmed with guide RNAs targeting transcripts absent in human cells, no unintended DNA damage occurred. The enzyme also showed high sensitivity to mismatches, meaning slight RNA differences protect healthy cells from being killed.

Caveats remain: this is early-stage research, and translating cell-culture results to in vivo cancer therapy or antiviral treatment involves many hurdles, including immune response, delivery precision, and long-term safety. Still, the platform opens doors to targeting disease states previously inaccessible to gene-editing tools.